Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.
Flowcyt Science-Based Company, Tehran, Iran.
Int J Nanomedicine. 2020 Aug 21;15:6263-6277. doi: 10.2147/IJN.S256104. eCollection 2020.
Nowadays, smart synthesized nanostructures have attracted wide attention in the field of stem cell nanotechnology due to their effect on different properties of stem cells.
GFc7 growth nanofactor was synthesized based on nanochelating technology as an iron-containing copper chelator nanocomplex. The effect of this nanocomplex on the expansion and differentiation of hematopoietic stem cells (HSCs) as well as its performance as a cryoprotectant was evaluated in the present study.
The results showed that the absolute count of CD34 and CD34CD38 cells on days 4, 7, 10 and 13; the percentage of lactate dehydrogenase enzyme on the same days and CD34CXCR4 population on day 10 were significantly increased when they were treated with GFc7 growth nanofactor in a fetal bovine serum (FBS)-free medium. This medium also led to delayed differentiation in HSCs. One noticeable result was that CD34CD38 cells cultured in an FBS medium were immediately differentiated into CD34CD38 cells, while CD34CD38 cells treated with GFc7 growth nanofactor in FBS medium did not show such an immediate significant differentiation. De-freezing GFc7-treated CD34 cells, which were already frozen according to cord blood bank protocols, showed a higher percentage of cell viability and a larger number of colonies according to colony-forming cell assay as compared to control.
It can be claimed that treating HSCs with GFc7 growth nanofactor leads to quality and quantity improvement of HSCs, both in terms of expansion in vitro and freezing and de-freezing processes.
如今,由于智能合成纳米结构对干细胞不同性质的影响,它们在干细胞纳米技术领域引起了广泛关注。
基于纳米螯合技术合成了 GFc7 生长纳米因子,作为一种含铁铜螯合纳米复合物。本研究评估了该纳米复合物对造血干细胞(HSCs)扩增和分化的影响及其作为冷冻保护剂的性能。
结果表明,在无胎牛血清(FBS)培养基中,用 GFc7 生长纳米因子处理后,第 4、7、10 和 13 天 CD34 和 CD34CD38 细胞的绝对计数、同天的乳酸脱氢酶酶百分比以及第 10 天的 CD34CXCR4 群体显著增加。该培养基还导致 HSCs 延迟分化。一个值得注意的结果是,在 FBS 培养基中培养的 CD34CD38 细胞立即分化为 CD34CD38 细胞,而用 GFc7 生长纳米因子处理的 CD34CD38 细胞在 FBS 培养基中没有表现出这种即时的显著分化。与对照相比,根据脐带血库协议已经冷冻的 GFc7 处理的 CD34 细胞的解冻显示出更高的细胞活力百分比和更大数量的集落形成细胞。
可以说,用 GFc7 生长纳米因子处理 HSCs 可提高 HSCs 的质量和数量,无论是在体外扩增还是冷冻和解冻过程中。